Limosilactobacillus fermentum ACA-DC 179 oral administration attenuates atherosclerosis progression in apolipoprotein E-deficient mice through murine gut microbiota modulation.

IF 3 4区医学 Q2 MICROBIOLOGY

Beneficial microbes Pub Date : 2025-03-31 DOI:10.1163/18762891-bja00064

I Ferrocino, G Zoumpopoulou, D Lali, R Anastasiou, A Agapaki, M Kazou, E Konstantakis, E Balafas, N P E Kadoglou, N Kostomitsopoulos, E Tsakalidou

{"title":"Limosilactobacillus fermentum ACA-DC 179 oral administration attenuates atherosclerosis progression in apolipoprotein E-deficient mice through murine gut microbiota modulation.","authors":"I Ferrocino, G Zoumpopoulou, D Lali, R Anastasiou, A Agapaki, M Kazou, E Konstantakis, E Balafas, N P E Kadoglou, N Kostomitsopoulos, E Tsakalidou","doi":"10.1163/18762891-bja00064","DOIUrl":null,"url":null,"abstract":"<p><p>Recent research findings have established a close relationship between gut microbiota and atherosclerosis development; hence, focus has shifted towards modifying gut microbiota through probiotics administration. We thereby investigated the impact of Limosilactobacillus fermentum ACA-DC 179 on the progression of atherosclerosis in apolipoprotein E-deficient (ApoE-/-) mice. Twelve-week-old ApoE-/- male and female mice were treated with low (106 CFU/mouse) or high (109 CFU/mouse) dose of L. fermentum ACA-DC 179 daily for 8 weeks. Microbiota of faeces during intervention and of gut content at study end was determined using classical microbiological and metataxonomic analyses. Additionally, blood serum biochemical markers and atherosclerotic lesions were evaluated in all animal groups. Classical microbiological analysis revealed high counts of Lactobacillus spp., Bifidobacterium spp. and Clostridium spp. for both male and female animals, regardless the treatment; however, at study end, L. fermentum ACA-DC 179 high dose managed to significantly increase Lactobacillus spp. counts of faeces of male mice. Metataxonomic analysis of faeces and gut content revealed significant differences among animal groups regarding either intestinal compartment, namely jejunum, ileum or colon, or probiotic treatment. A decrease in Lachnoclostridium and an increase in Erysipelatoclostridium were observed in faecal samples following probiotic treatment. This effect was consistent with the results obtained for all gut compartment samples of mice receiving the high dose of L. fermentum ACA-DC 179. Concerning main metabolism-related blood biomarkers, triglycerides decreased in animal groups of both sexes receiving L. fermentum ACA-DC 179. Moreover, L. fermentum ACA-DC 179 high dose significantly reduced atherosclerotic lesions in both male and female mice. Overall, our findings indicate that L. fermentum ACA-DC 179 administration attenuated the development of atherosclerosis in ApoE-/- mice supporting its beneficial potential in relevant human studies. Altered gut microbiota seems to play a significant role to this phenomenon and further studies should be conducted to elucidate underlying mechanisms.</p>","PeriodicalId":8834,"journal":{"name":"Beneficial microbes","volume":" ","pages":"1-18"},"PeriodicalIF":3.0000,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Beneficial microbes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1163/18762891-bja00064","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Recent research findings have established a close relationship between gut microbiota and atherosclerosis development; hence, focus has shifted towards modifying gut microbiota through probiotics administration. We thereby investigated the impact of Limosilactobacillus fermentum ACA-DC 179 on the progression of atherosclerosis in apolipoprotein E-deficient (ApoE-/-) mice. Twelve-week-old ApoE-/- male and female mice were treated with low (106 CFU/mouse) or high (109 CFU/mouse) dose of L. fermentum ACA-DC 179 daily for 8 weeks. Microbiota of faeces during intervention and of gut content at study end was determined using classical microbiological and metataxonomic analyses. Additionally, blood serum biochemical markers and atherosclerotic lesions were evaluated in all animal groups. Classical microbiological analysis revealed high counts of Lactobacillus spp., Bifidobacterium spp. and Clostridium spp. for both male and female animals, regardless the treatment; however, at study end, L. fermentum ACA-DC 179 high dose managed to significantly increase Lactobacillus spp. counts of faeces of male mice. Metataxonomic analysis of faeces and gut content revealed significant differences among animal groups regarding either intestinal compartment, namely jejunum, ileum or colon, or probiotic treatment. A decrease in Lachnoclostridium and an increase in Erysipelatoclostridium were observed in faecal samples following probiotic treatment. This effect was consistent with the results obtained for all gut compartment samples of mice receiving the high dose of L. fermentum ACA-DC 179. Concerning main metabolism-related blood biomarkers, triglycerides decreased in animal groups of both sexes receiving L. fermentum ACA-DC 179. Moreover, L. fermentum ACA-DC 179 high dose significantly reduced atherosclerotic lesions in both male and female mice. Overall, our findings indicate that L. fermentum ACA-DC 179 administration attenuated the development of atherosclerosis in ApoE-/- mice supporting its beneficial potential in relevant human studies. Altered gut microbiota seems to play a significant role to this phenomenon and further studies should be conducted to elucidate underlying mechanisms.

查看原文本刊更多论文

通过调节小鼠肠道菌群，口服发酵乳酸杆菌ACA-DC 179减轻载脂蛋白e缺乏小鼠动脉粥样硬化的进展。

近年来的研究发现，肠道微生物群与动脉粥样硬化的发展密切相关；因此，重点已转向通过益生菌管理来改变肠道微生物群。因此，我们研究了发酵乳酸杆菌ACA-DC 179对载脂蛋白e缺乏（ApoE-/-）小鼠动脉粥样硬化进展的影响。12周龄ApoE-/-雄性和雌性小鼠分别给予低剂量（106 CFU/只）或高剂量（109 CFU/只）发酵乳杆菌ACA-DC 179，连续8周。使用经典的微生物学和元分类学分析确定干预期间粪便和研究结束时肠道内容物的微生物群。此外，对所有动物组的血清生化指标和动脉粥样硬化病变进行评估。经典微生物学分析显示，无论处理方式如何，雄性和雌性动物的乳酸杆菌、双歧杆菌和梭状芽胞杆菌的数量都很高；然而，在研究结束时，发酵乳杆菌ACA-DC 179高剂量能显著增加雄性小鼠粪便中乳酸杆菌的数量。粪便和肠道内容物的元分类分析显示，动物组之间在肠隔室（即空肠、回肠或结肠）或益生菌治疗方面存在显著差异。在益生菌治疗后的粪便样本中观察到绒梭菌的减少和丹毒梭菌的增加。这种效果与接受高剂量发酵乳杆菌ACA-DC 179的所有小鼠肠道样本的结果一致。在主要代谢相关的血液生物标志物方面，摄入发酵乳杆菌ACA-DC 179的男女动物组甘油三酯均下降。此外，发酵乳杆菌ACA-DC 179高剂量可显著减少雄性和雌性小鼠的动脉粥样硬化病变。总之，我们的研究结果表明，发酵乳杆菌ACA-DC 179减轻ApoE-/-小鼠动脉粥样硬化的发展，支持其在相关人类研究中的有益潜力。肠道菌群的改变似乎在这一现象中起着重要作用，应该进行进一步的研究来阐明潜在的机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Beneficial microbes MICROBIOLOGY-NUTRITION & DIETETICS

CiteScore

7.90

自引率

1.90%

发文量

审稿时长

>12 weeks

期刊介绍： Beneficial Microbes is a peer-reviewed scientific journal with a specific area of focus: the promotion of the science of microbes beneficial to the health and wellbeing of man and animal. The journal contains original research papers and critical reviews in all areas dealing with beneficial microbes in both the small and large intestine, together with opinions, a calendar of forthcoming beneficial microbes-related events and book reviews. The journal takes a multidisciplinary approach and focuses on a broad spectrum of issues, including safety aspects of pro- & prebiotics, regulatory aspects, mechanisms of action, health benefits for the host, optimal production processes, screening methods, (meta)genomics, proteomics and metabolomics, host and bacterial physiology, application, and role in health and disease in man and animal. Beneficial Microbes is intended to serve the needs of researchers and professionals from the scientific community and industry, as well as those of policy makers and regulators. The journal will have five major sections: * Food, nutrition and health * Animal nutrition * Processing and application * Regulatory & safety aspects * Medical & health applications In these sections, topics dealt with by Beneficial Microbes include: * Worldwide safety and regulatory issues * Human and animal nutrition and health effects * Latest discoveries in mechanistic studies and screening methods to unravel mode of action * Host physiology related to allergy, inflammation, obesity, etc. * Trends in application of (meta)genomics, proteomics and metabolomics * New developments in how processing optimizes pro- & prebiotics for application * Bacterial physiology related to health benefits